Gynesonics announced that it has submitted its 510(k) Premarket Notification to the FDA for its Sonata System.
The Sonata System is a uterus preserving, incision-free uterine fibroid treatment that was designed to treat fibroids transcervically with radiofrequency energy.
“Submission of the 510(k) application is an important milestone for our company,” Chris Owens, president and CEO of Gynesonics, said in a press release. “We are focused now on responding to any questions or requests from the FDA in support of a timely submission review, and preparations for initial commercial launch in the U.S. in 2018.”
Acessa Health also has a system to treat uterine fibroids with reduced blood loss, hospitalization time and readmission rates. The system uses radiofrequency ablation guided by ultrasound to remove fibroids.
Gynesonics suggests that hysteroscopic myomectomy is the only method available to treat fibroids transcervically and it is limited to smaller submucosal fibroids and limited to 15% of fibroids. The Sonata System is designed to treat nearly 80% of all fibroids.
“Based on the impressive 12-month results achieved in our Sonata IDE Pivotal Trial included in our FDA submission, we believe the Sonata System has the potential to be a groundbreaking treatment and a new standard of care for literally millions of women worldwide who currently have limited options for treating uterine fibroids. Sonata is the only option that can treat the majority of fibroids with a transcervical incision-free uterine-sparing approach,” Owens said.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.